4-Piperidino-cyclohexanol | 1531-95-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Piperidino-cyclohexanol
• 英文别名: 4-(1-piperidyl)-cyclohexanol；Cyclohexanol, 4-piperidino-；4-piperidin-1-ylcyclohexan-1-ol
• CAS: 1531-95-9
• 化学式: C₁₁H₂₁NO
• 分子量: 183.294
• InChiKey: VHFKXROBNKLENX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Piperidino-cyclohexanol 生成 4-Piperidinylcyclohexanon
  参考文献：
  名称：

  MOORADIAN A.; DUPONT P. E.; HLAVAC A. G.; ACETO M. D.; PEARL J., J. MED. CHEM. , 1977, 20, NO 4, 487-492

  摘要：

  DOI：
• 作为产物：
  描述：

  (4-piperidin-1-ylcyclohex-3-en-1-yl) benzoate 生成 4-Piperidino-cyclohexanol
  参考文献：
  名称：

  MOORADIAN A.; DUPONT P. E.; HLAVAC A. G.; ACETO M. D.; PEARL J., J. MED. CHEM. , 1977, 20, NO 4, 487-492

  摘要：

  DOI：

文献信息

• Tetrahydro-benzthiazoles, the preparation thereof and their use as
  申请人：Dr. Karl Thomae GmbH

  公开号：US04731374A1

  公开（公告）日：1988-03-15

  This invention relates to new tetrahydrobenzthiazoles of general formula ##STR1## wherein R.sub.1 represents a hydrogen atom, an alkyl group, an alkenyl or alkynylk group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the above mentioned phenyl nuclei may each be substituted by 1 or 2 halogen atoms, R.sub.2 represents a hydrogen atom or an alkyl group, R.sub.3 represents a hydrogen atom, an alkyl group a cycloalkyl group, an alkenyl or alkynyl group, an alkanoyl group, a phenyl alkyl or phenyl alkanoyl group, while the phenyl nucleus may be substituted by flurorine, chlorine or bromine atoms, R.sub.4 represents a hydrogen atom, an alkyl group, an alkyl or alkenyl group, or R.sub.3 and R.sub.4 together with the nitrogen atom between them represent a pyrrolidino, piperidino, hexamethyleneimino or morpholino group, the enantiomers and the acid addition salts thereof. The compounds of general formula I above in which one of the groups R.sub.1 or R.sub.3 or both groups R.sub.1 and R.sub.3 represent an acyl group are valuable intermediate products for preparing the other compounds of general formula I which have valuable pharmacological properties. The new compounds may be prepared using methods known per se.

  这项发明涉及一种新的四氢苯并噻唑类化合物，其一般化学式为##STR1##其中R.sub.1代表氢原子、烷基、烯基或炔基、醇酰基、苯基烷基或苯基醇酰基，上述提到的苯核可以分别被1或2个卤素原子取代，R.sub.2代表氢原子或烷基，R.sub.3代表氢原子、烷基、环烷基、烯基或炔基、醇酰基、苯基烷基或苯基醇酰基，而苯核可以被氟、氯或溴原子取代，R.sub.4代表氢原子、烷基、烷基或烯基，或者R.sub.3和R.sub.4与它们之间的氮原子一起代表吡咯啉基、哌啶基、己亚甲基胺基或吗啉基，以及其对映体和酸盐。上述一般式I中的化合物中，R.sub.1或R.sub.3中的一个或两个代表酰基的基是制备具有有价值的药理特性的一般式I其它化合物的有价值的中间体。这些新化合物可以使用已知方法制备。
• [EN] CDK8 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CDK8 ET APPLICATIONS DE CEUX-CI
  申请人：NIMBUS IRIS INC

  公开号：WO2014194201A2

  公开（公告）日：2014-12-04

  The present invention provides methods of using compounds of formula I: and compositions thereof for the inhibition of CDK8, and the treatment of CDK8-mediated disorders.

  本发明提供了使用式I的化合物及其组合物来抑制CDK8和治疗CDK8介导的疾病的方法。
• Quinazoline Derivative
  申请人：Mizutani Takashi

  公开号：US20080275069A1

  公开（公告）日：2008-11-06

  This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (I) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

  本发明提供了式（I）的化合物或其药学上可接受的盐，其中R1代表较低的烷基等；R2和R3相同或不同，分别代表氢原子等；R4代表式（I）的取代基等；X1代表NH、O或S；Y代表N或C；Ar是由芳基衍生的二价取代基等，通过去除其中的两个氢原子而得到；环A表示5-或6-成员杂芳基基团；这些化合物具有组胺H3受体拮抗作用或组胺H3受体反向激动剂作用，并且对于预防或治疗代谢系统疾病、循环系统疾病或神经系统疾病是有用的。
• Heterocyclic Compounds as CCR2 Antagonists
  申请人：Bower Justin Fairfield

  公开号：US20110136820A1

  公开（公告）日：2011-06-09

  Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

  化合物的公式为(I)Q-L-W—C(═X)—Z—P，其中Q为公式—N(R1)(R2)的胺基；L为烷基或杂环烷基烷基连接物；W为6-或7-成员的脂肪环，包括与基团L和C(X)分别连接的环原子Y1和Y2，且Y1和Y2独立地选自N和C；X为O、N、N—CN或S；Z为NR3；P为可选取代的单环或双环芳基或杂芳基基团；以及其药学上可接受的盐或溶剂，可用于治疗C-C趋化因子介导的疾病。
• IRAK INHIBITORS AND USES THEREOF
  申请人：NIMBUS IRIS, INC.

  公开号：US20130231328A1

  公开（公告）日：2013-09-05

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。